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Introduction: Recently, prescribing antipsychotics for children and adolescents has been
increasing in many countries. These drugs are often prescribed off-label, although
antipsychotics have been associated with adverse effects. We determined the recent
incidence of antipsychotic use among children and adolescents in Finland.
Methods: Finnish National Prescription Register including all Finnish inhabitants receiving
reimbursement for pharmaceuticals was searched for subjects of 1 to 17 years of age who
had started an antipsychotic drug between January 1, 2008, and December 31, 2017 (n =
26,353). Between 2008 and 2017, the range of number of Finnish children and
adolescents aged 1 to 17 years was 1.01 to 1.03 million/year. The incidence was
calculated by dividing the number of new users by all age- and sex-matched Finnish
inhabitants in the year.
Results: Between 2008 and 2017, the incidence of antipsychotic use among children
and adolescents increased from 2.1 to 3.8 per 1000 individuals, respectively. In children
aged 7 to 12 years, the incidence of antipsychotic use 1.4-folded (from 1.9 (95% CI: 1.8–
2.0) to 2.7 (95% CI: 2.5–2.9) per 1000) with a cumulative increase of 0.2% per year (c2 =
51.0, p < 0.0001). In adolescents aged 13 to 17 years, the incidence 2.2-folded (from 4.3
(95% CI: 4.1–4.5) to 9.4 (95% CI: 9.1–9.8) per 1000) with a cumulative increase of 0.6%
per year (c2 = 590.3, p < 0.0001). The increase in the incidence of use was steeper in girls
(2.3-fold) than in boys (1.4-fold) (c2 = 85.6, p < 0.0001), especially between 2015 and
2017 (1.6-fold and 1.2-fold, respectively) (c2 = 151.7, p < 0.0001). The year 2011 was the
turning point when the incidence in girls exceeded the incidence in boys, and the
incidence of quetiapine use exceeded that of risperidone use.
Conclusions: The incidence of antipsychotic use increased between 2008 and 2017,
especially in adolescent girls. The use of quetiapine increased, although it has few official
indications in children and adolescents. Future studies should investigate the reasons for
increasing use of antipsychotics, especially quetiapine, in children and adolescents.
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The prescribing of psychotropic drugs in children and
adolescents has increased in many countries during the last
decade (1–4). This change is mainly due to the growing use of
stimulants (2), but the use of antipsychotic drugs is also on the
rise (2, 3, 5–7). The prevalence of antipsychotic use in children
and adolescents varies from 0.5 to 30.8 per 1000 individuals in
different countries (6). Between 2005 and 2012, the prevalence of
antipsychotic drug use in children and adolescents increased
globally, whereas at the same time in the US the prevalence
slightly declined (8). It is not clear, however, if the increase in the
prevalence of antipsychotic use is a result of increase of new
antipsychotic treatments.
Second-generation antipsychotics (SGAs) have been
associated with fewer serious adverse effects, such as
extrapyramidal symptoms and tardive dyskinesia, than first-
generation antipsychotics (FGAs) (9). Thus, clinicians seem to
have assumed that SGAs are a safer treatment regime than FGAs
in children and adolescents (10), contributing to the increase in
use of SGAs in many countries (6). The prescribing of FGAs in
patients aged under 18 years in the US has simultaneously
steadily diminished, whereas in Europe FGAs remain popular
(9). SGAs have multiple side effects (11, 12). Recent studies have
shown that SGAs may be associated with weight gain, increased
appetite, obesity, type 2 diabetes, cardiovascular morbidity,
abnormal involuntary movements, and sedation (7, 9, 11,
13–16).
In children and adolescents, antipsychotic drugs are
frequently used off-label (17, 18). In subjects under 18 years of
age, 69% to 92% of the antipsychotics are prescribed without
official indications (3, 19, 20). In the US and Europe, the three
most commonly prescribed SGAs are in descending order
risperidone, quetiapine, and aripiprazole (6, 16, 21).
Risperidone has only three official indications in children and
adolescents in the US and in the EU (schizophrenia in 14- to 17-
year-olds, bipolar I disorder with manic or mixed episodes in 10-
to 17-year-olds, and treatment of aggression and irritability in
autistic disorder in 5- to 17-year-olds) (22). Conversely, the only
official indication in children and adolescents for risperidone in
Finland is a maximum of six weeks' use for aggressive behavior in
intellectually disabled children aged over 5 years, whereas
quetiapine has no official indication in drug treatment of
Finnish children and adolescents. Aripiprazole is indicated in
Finnish children and adolescents to treat schizophrenia (age
above 15 years) or bipolar I disorder for less than 12 weeks (age
above 13 years). The fore-mentioned indications are obtained
from the summaries of product characteristics accepted by
medical authorities (Finnish Medicines Agency, European
Medicines Agency). A retrospective study in US showed that
attention-deficit hyperactivity disorder (ADHD) was the most
common diagnosis in children and adolescents treated with
SGAs (17). Other frequent diagnoses in SGA users were
conduct disorders, autism, mood disorders, bipolar disorder,
tic, Tourette syndrome, aggression, insomnia, and anxiety
disorders (1, 3, 16, 23, 24). These data suggest that
antipsychotics may be prescribed liberally for many conditions.Frontiers in Psychiatry | www.frontiersin.org 2It is not clear whether the increase in the use of SGAs is a result of
an increased number of new antipsychotic users. Remarkably,
few studies have investigated the incidence of antipsychotic use
in children and adolescents (7, 25–27), and it can only be
comprehensively studied in countries with nationwide registers
on drug prescriptions (2, 7).
In this nationwide Finnish register study, we report changes in
the incidence of antipsychotic use in children and adolescents
between 2008 and 2017. Little is known on the incidence of
antipsychotic use in the recent years, and the changes in the
number of new users of antipsychotic is reflected more precisely
by incidence rather than prevalence. Specifically, we evaluate how
starting a new antipsychotic drug has changed in different age
groups and between sexes. In new antipsychotic users, we
characterize frequency of used substances, and diagnoses
in children and adolescents with severe mental and
behavioral disorders.MATERIALS AND METHODS
All Finnish residents (approximately 5.5 million) are covered
under the National Health Insurance, and drug reimbursements
are recorded in the Finnish National Prescription Register
maintained by the Social Insurance Institution of Finland (SII).
The register contains information on the patient and the
prescription. We collected data on patients` birth date, gender,
dispensing date of the prescription, place of residence, and
reimbursement. In the register, all medications are coded
according to the Anatomical Therapeutic Chemical (ATC)
classification system. We extracted data on the subjects who
received reimbursements for antipsychotic medication (all ATC
N05A codes). Although, lithium is not an antipsychotic, it was
included in the analyses since it is included in the group of
antipsychotics in the ATC classification (N05AN01) and it's uses
are similar to that of antipsychotics', although more narrow. The
definition of on- and off-label SGA use was based on the
indications in the summaries of product characteristics accepted
by medical authorities (Finnish Medicines Agency, European
Medicines Agency). The age of the patient plays a significant role
for indications in the summaries of product characteristic. Most of
the antipsychotics are not indicated for patients under 18 years.
Between 2008 and 2017, the yearly mean of all 1 to 17 year old
Finnish inhabitants was 1.02 million (range, 1.01–1.03 million/
year). The study population included children and adolescents
aged between 1 and 17 years, who had received antipsychotic
drug reimbursements between January 1, 2008, and December
31, 2017, in Finland (n = 70,012). We included all reimbursed
antipsychotic prescriptions including small packages in the
analyses. We defined a new user (i.e. incidence) as a subject
who had not filled a prescription of antipsychotics in the
previous 730 days. Thus, to cover the wash-out period for new
users in 2008, we searched the data from 1 January 2006 to 31
December 2007. The date of the initial purchase was determined
as the index date. Subjects' age at treatment initiation was
calculated as the difference between birth date and index date.April 2020 | Volume 11 | Article 316
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users by all age- and sex-matched Finnish inhabitants in the year.
To describe the new antipsychotic users further, we gathered
register-based diagnostic information on the children and
adolescents with severe mental and behavioral disorders from
the Register of Disability Benefits of SII. In Finland, children and
adolescents with a severe somatic or a psychiatric disorder
(mental and behavioral disorders) causing disability and who
need regular care, attention, and rehabilitation are entitled to a
disability allowance. In 2017, according to SII statistic database
Kelasto 3.7% of Finnish children and youth under 16 years of age
received disability allowance (www.kela.fi/web/en/statistical-
database-kelasto). Of these children 56% had a psychiatric
disorder diagnosis. During the last 10 years, the number of the
yearly recipients has remained constant. The allowance is
intended to provide monetary support for the families of
children with disabilities. In the register, the diagnoses of cases
with the allowance are coded according to the International
Classification of Disease, 10th Revision (ICD-10) and are
categorized into primary and secondary diagnoses, the former
of which was used in the analyses.
The study population was divided into four age groups (1–6,
7–12, 13–15, and 16–17 years) (Figure 1B). The season of
treatment initiation was categorized into summer (June-
August), autumn (September-November), winter (December-
February), and spring (March-May). The drug reimbursement
rate was divided into two categories: those with a reimbursement
rate of 40% (Basic Refund Category) and to those with a
reimbursement rate of 100% (Special Refund Category). The
latter group included intellectually disabled persons with
aggressive behavior, children and adolescents diagnosed with
psychoses or depressive disorders with psychosis or mania.
The study was based only on register data, and thus, no
permission from an Ethics Board was required according to the
Finnish Medical Research Act. The Social Insurance Institution
of Finland approved the use of data for the study.
Statistical Analyses
The incidence of antipsychotic drug use with 95% confidence
interval (CI) was calculated by dividing the number of new users
by all age- and sex-matched Finnish inhabitants in the year (data
obtained from SII). Additionally, we determined a cumulative
growth (% per year) in new antipsychotic users. The cumulative
growth was calculated by dividing the number of new users by
the number of subjects at risk during the follow-up period.
Comparisons between years, sexes, and age groups were
performed with Chi-Square test or Fisher's exact test. Statistical
analyses were performed with SPSS statistical software for
Windows (version 22.2.2, Chicago, IL, USA). Statistical
significance was set at P < 0.05.RESULTS
Between 2008 and 2017, antipsychotic drug was started in 26 353
subjects (i.e. new users), 12 715 (48.2%) of whom were boys.Frontiers in Psychiatry | www.frontiersin.org 3Among the newusers, the largest age groupwas adolescents aged16
to 17 years (n = 9,813, 37.2%), followed by adolescents aged 13 to 15
years (n = 8,429, 32.0%) and children aged 7 to 12 years (n = 7,470,
28.3%). For additional background data, the prevalences of
antipsychotic use in children and adolescents between 2008 and
2017 are presented in Supplementary Figure 1.Change in Incidence of Antipsychotic Use
Between 2008 and 2017, the incidence of antipsychotic use
among children and adolescents increased from 2.1 to 3.8 per
1000 individuals, respectively (Figure 1A). The incidence of
antipsychotic use 1.4-folded (from 1.9 (95% CI: 1.8–2.0) to 2.7
(95% CI: 2.5–2.9) per 1000) with a cumulative increase of 0.2%
per year in children aged 7 to 12 years (c2 = 51.0, p < 0.0001). In
adolescents aged 13 to 17 years, the incidence 2.2-folded (from
4.3 (95% CI: 4.1–4.5) to 9.4 (95% CI: 9.1–9.8) per 1,000) with a
cumulative increase of 0.6% per year (c2 = 590.3, p < 0.0001)
(Figure 1B).
Only 641 (2.4%) of the new users were under 7 years old, and
500 (78.0%) of these were boys. In this subgroup, the change in theA
B
FIGURE 1 | The incidence of antipsychotic use among all children and
adolescents (A) and in different age groups (B) in Finland between 2008 and
2017.April 2020 | Volume 11 | Article 316
Varimo et al. Antipsychotic Use in Children and Adolescentsincidence of antipsychotic use did not increase significantly
between 2008 and 2017 (from 0.2 (95% CI: 0.2–0.3) to 0.2 (95%
CI: 0.2–0.3) per 1,000, the cumulative increase was 0.02% per year)
(c2 = 1.0, p = 0.31) (Figure 1B). In all age groups, the increase in
incidence between 2008 and 2017 was stronger in girls than in
boys, as the incidence of antipsychotic use 2.3-folded in girls and
1.4-folded in boys (c2 = 85.6, p < 0.0001) (Table 1). In detail, the
largest increase in the incidence was observed between 2015 and
2017, and during this period, the incidence 1.6-folded in girls and
1.2-folded in boys (c2 = 151.7, p < 0.0001) with a cumulative
increase of 0.4% and 0.3% per year, respectively (Figure 1A).
Between 2013 and 2015, the incidence remained constant in both
sexes (Figure 1A). Thereafter, the incidence increased
substantially, especially in girls (Figure 1A). The year 2011 was
the turning point when the incidence in girls exceeded that in
boys, and the incidence of quetiapine use exceeded that of
risperidone use.The Diagnoses of Children and
Adolescents With Disability Allowance in
New Antipsychotic Users
Between 2008 and 2017, altogether 8,464 (32.1%) of the new
antipsychotic users had received disability allowance. During the
study period, the three most common mental and behavioral
disorder (F00-F99) diagnoses related to being granted a disability
allowance were hyperkinetic disorders (F90) (n = 1,532, 20.4%),
pervasive developmental disorders (F84) (n = 1,147, 15.3%), and
mixed disorders of conduct and emotions (F92) (n = 654, 8.7%)
(Supplementary Table 1). These diagnoses accounted for 44.4%
of all mental and behavioral disorder diagnoses in children and
adolescents with disability allowance. Of all mental and
behavioral disorder diagnoses in children and adolescents with
disability allowance, 5,252 (70.1%) were diagnoses without
official indications for antipsychotic treatment. In new
antipsychotic users aged under 7 years, 467 (74.1%) were
granted a disability allowance, and the three most common
diagnoses were pervasive developmental disorders (F84), mixed
specific developmental disorders (F83), and hyperkinetic
disorders (F90) (Supplementary Table 1). Between 2008 and
2017, we observed a significant increase in hyperkinetic disorders
(F90) (c2 = 6.4, p = 0.01) and pervasive developmental disorders
(F84) (c2 = 7.2, p = 0.01) in new antipsychotic users aged 7 to 12
years with disability allowance (Supplementary Table 2). At the
same time, the frequency of pervasive developmental disorders
(F84) (c2 = 4.9, p = 0.03) and depressive episode (F32) (c2 = 8.8,
p = 0.003) increased in new antipsychotic users aged 13 to 17
years (Supplementary Table 2).
Between 2008 and 2017, the four most commonly first
purchased antipsychotic drugs in children and adolescents who
started antipsychotics (i.e. new users) were quetiapine (n = 13 338,
50.6% of all antipsychotic users), risperidone (n = 10 690, 40.6%),
olanzapine (n = 792, 3.0%), and aripiprazole (n = 500, 1.9%)
(Table 1). These four substances accounted for the majority of
new antipsychotic prescriptions (n = 25 320; 96.1%). During the
study period, quetiapine was initiated more frequently in girls thanFrontiers in Psychiatry | www.frontiersin.org 4in boys, and the increase of incidence was steepest during the last
years (Figure 2). Before the year 2011, risperidone was the most
commonly prescribed new antipsychotic; thereafter, the incidence
of quetiapine prescriptions has exceeded risperidone. During the
study period risperidone was the most prescribed new
antipsychotic drug in subjects aged under 7 years (n = 583,
91.0%) (Supplementary Table 1). New antipsychotic drug was
initiated most commonly in autumn (September-November) (n =
7396, 28.1%, c2 = 761.0, p < 0.0001). During the study period, 333
(1.3%) prescriptions were reimbursed in Special Refund category
and the rest in Basic Refund category. Of the 333 prescriptions,
288 (86%) were prescribed to persons with psychoses or depressive
disorders with psychosis or mania and 45 (24%) for aggressive
behavior in intellectually disabled children.DISCUSSION
In this nationwide register study, we found that the incidence of
antipsychotic use has increased in children and adolescents
during the last 10 years, with the increase being particularly
strong between 2015 and 2017. From 2011, the incidence in girls
exceeded that in boys, and at the same time the incidence of
quetiapine treatment exceeded that of risperidone treatment.
The incidence of antipsychotic use increased in children and
adolescents in Finland between 2008 and 2017. A similar rise in
the incidence of antipsychotic use aged under 18 years has been
reported in Dutch population (7). In our study, the largest
incidence of antipsychotic use was observed in adolescents
aged 16 to 17 years, followed by subjects aged 13 to 15 years
and 7 to 12 years. The increase in incidence of antipsychotic use
may have several reasons. Nowadays, psychiatric outpatient care
is more easily accessible for children and adolescents, and the
views of parents and physicians regarding the prescribing of
antipsychotic drugs have been reported to be more favourable (7,
19, 25, 28). Importantly, antipsychotic drugs have been usedFIGURE 2 | The incidence of quetiapine use among Finnish boys and girls
aged 1 to 17 years between 2008 and 2017.April 2020 | Volume 11 | Article 316
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disorders (3, 17, 25, 29). We speculate clinicians may also
prescribe antipsychotics, especially quetiapine, in children and
adolescents to treat depression and anxiety disorders and
insomnia reflecting the use of quetiapine in adult population
(30). Finally, the limited availability of psychotherapy and the
greater commitment that it entails relative to prescribing
medication could favor the use of antipsychotic drugs (17, 28).
The year 2011 was the turning point when the incidence of
antipsychotic use in girls exceeded that in boys, and this trend
remained until the end of the follow-up. In Finland, the prevalence
of emotional problems has increased more in adolescent girls than
in adolescent boys during the last 20 years (31). Conversely, the use
of antipsychotics in all age groups has been reported to be more
common in boys than in girls (7, 17, 32), although the gap between
the sexes narrows with age in adolescence (17, 32). Similar to our
results, a recent Dutch register study reported that the incidence on
antipsychotic use in girls exceeded that in boys in 2015 (7). Our
finding of the rapid increase in the incidence of antipsychotic use
in girls may be a result of multiple short treatment periods or
antipsychotics being prescribed to girls to treat symptoms or
mental disorders such as insomnia, anxiety disorders, mood
disorders, and agitation (3, 19, 20, 24, 33). Additionally, previous
studies have shown that in all age groups boys are treated with
antipsychotics for longer periods than girls (7). Future studies
should investigate the duration of the antipsychotic treatment and
how the medication follow-up is actualized. It is important to pay
careful attention to monitoring the harms and benefits of
antipsychotic treatment and to discontinue ineffective treatment
in children and adolescents (10, 34).
In our study, quetiapine replaced risperidone as the most
prescribed new antipsychotic drug after 2011. A similar turning
point (2012) was observed in Denmark (35). Our finding is
consistent with a previous study that reported quetiapine as the
most common antipsychotic drug in adolescents older than 14
years and found a significant increase in the frequency of
quetiapine use in subjects under 14 years of age (32). In our
study, quetiapine was initiated more frequently in girls than in
boys, especially in girls during the last two years of the study
period. Based on our clinical expertise we hypothesise that low
dose (i.e., 25–75 mg daily) quetiapine was prescribed in short
treatment durations in girls to treat anxiety disorders and
insomnia. To this end, a previous study reported a high use of
quetiapine for insomnia in adolescent girls admitted to
psychiatric inpatient care (36). Furthermore, the study found
that quetiapine was prescribed for only insomnia in 57% of the
admitted girls, and 25% were diagnosed with anxiety disorder,
depressive disorder, eating disorder, or personality disorder (36).
This is remarkable as quetiapine has only a few official
indications in children and adolescents (schizophrenia 13 years
and older, bipolar disorder manic and mixed episodes 10 years
and older) (US Food and Drug Administration) in the US. This
probably reflects the use of quetiapine in adults, as a Norwegian
register study reported that the median daily dose of quetiapine
was less than 100 mg, and that only approximately 4% of users
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Varimo et al. Antipsychotic Use in Children and Adolescentsquetiapine for an approved indication (37). Importantly, the use
of quetiapine in children and adolescents is associated with a
considerable risk of side effects such as weigh gain, increased
triglycerides, blood pressure and heart rate, and daytime sedation
which may occur early after treatment initiation (15, 38–41). In
Finland, quetiapine has no official indications in subjects aged
under 18 years, which suggests substantial off-label use of
quetiapine in Finnish adolescents.
In children aged 7 to 12 years with disability allowance,
hyperkinetic disorders and pervasive developmental disorders
were the most common diagnoses in new antipsychotic users,
whereas pervasive developmental and depressive disorders
were enriched in new users aged 13 to 17 years. In general,
the children and adolescents with a more severe disorder need
more care and attention and are more likely to be entitled to a
disability allowance than the subjects with a less severe
disorder. This translates into the children and adolescents in
the disability register having on average a more severe
diagnostic status than those not in the register. At the same
time, we agree that the diagnoses of this subsample may not be
generalized to all new SGA users. In the EU and the US, the
most common diagnoses in children and adolescents who
receive antipsychotics are hyperkinetic disorder, conduct
disorder, autism spectrum disorder, mental retardation,
depression, and bipolar disorder (7, 17, 25, 28, 32).
Conversely, studies in the US and in the Netherlands have
reported the two most common diagnoses in new antipsychotic
users to be bipolar disorder and schizophrenia (7, 25).
Supporting our finding, the incidence of behavioral disorders
and autism spectrum disorders have been found to be enriched
in early and middle childhood, whereas depression and anxiety
disorders increase in adolescence (17, 24, 26). While serious
mental disorders, such as schizophrenia and psychotic
disorders, have not increased among new antipsychotic users
aged under 18 years (25), we and others have observed an
increase in prescribing antipsychotic drugs (3, 25).
The main strength of this study is that it is a comprehensive
nationwide register study that covers all reimbursed outpatient
prescription drug purchases in children and adolescents aged 1
to 17 years. This study focused on incidence rather than
prevalence, since the former describes more precisely the
changes in the number of new users. The data included a two-
year wash-out time to select subjects who were truly new
antipsychotic users. The present study includes limitations that
should be addressed. The data included only outpatient use of
antipsychotics, and non-prescribed medicines were not included
indicating that a small number of prescriptions were not
recorded in the register. Our data on diagnoses was
incomplete, since the data did not include diagnoses for all
users, only for users with disability allowance (32.1% of our
SGA users). Further, the data did not include the indications for
SGA prescriptions. The use of antipsychotics could not be
confirmed, and we can only assume that the purchased
antipsychotics were used as prescribed. To get more specific
information on SGA use, future studies might benefit fromFrontiers in Psychiatry | www.frontiersin.org 6combining the data of prescription register and medical
records. This study did not address treatment duration of SGA
use, which may have changed in children and adolescents during
the study period and may partly explain the increase in the
i n c i d e n c e o f a n t i p s y c h o t i c u s e . Th i s w a r r a n t s
further investigation.
In conclusion, the incidence of antipsychotic use increased
during the study period, especially in adolescent girls between
2015 and 2017. In 2011, quetiapine overtook risperidone as the
most prescribed antipsychotic, and the incidence of
antipsychotic use in girls exceeded that in boys. We observed
that antipsychotic drugs were prescribed almost exclusively for
off-label indications in children and adolescents. Future studies
should investigate the duration of antipsychotic treatments and
the reasons for the increased use of antipsychotics,
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